Hikma Signs an Exclusive License Agreement with Glenmark to Commercialize Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) in the US

 Hikma Signs an Exclusive License Agreement with Glenmark to Commercialize Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) in the US

Hikma Signs an Exclusive License Agreement with Glenmark to commercialize Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) in the US

Shots:

  • Glenmark to receive up front, regulatory & commercial milestones along with royalties on sales of Ryaltris in the licensed territory. Glenmark will continue the development of the therapy and is responsible for the US FDA approval
  • Following the approval, Hikma will commercialize the therapy in the US. The focus of the collaboration is to advance the Glenmark’s position in nasal allergy spray and to boost its specialty business while the addition of Ryaltris to Hikma’s portfolio expands its nasal spray leadership in the US
  • Ryaltris is an investigational FDC nasal spray, evaluated in seven clinical studies in 4000+ adults & adolescent patients aged ≥12yrs. to treat seasonal allergic rhinitis (SAR)

Click here ­to­ read full press release/ article | Ref: Hikma | Image: Equity Pandit

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post